Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: Impact of revised WHO guidelines;La coordinación de la terapia antirretroviral en un hospital camboyano tras el diagnóstico de tuberculosis: El impacto de las directrices revisadas de la OMS

Bulletin of the World Health Organization

Volumn 91, Issue 3, 2013, Pages 195-206

  Choun, Kimcheng ^a   Pe, Reaksmey ^a   Thai, Sopheak ^a   Lorent, Natalie ^b   Lynen, Lutgarde ^b   van Griensven, Johan ^b  

^a Sihanouk Hospital Centre of Hope   (Cambodia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

COHORT ANALYSIS; DISEASE TREATMENT; GUIDELINE; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; IDENTIFICATION METHOD; IMPLEMENTATION PROCESS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; ARTICLE; CAMBODIAN; CD4 LYMPHOCYTE COUNT; DELAYED DIAGNOSIS; DRUG ERUPTION; FEMALE; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT MONITORING; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; THERAPY DELAY; TOXIC HEPATITIS; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CAMBODIA; CD4 LYMPHOCYTE COUNT; COMORBIDITY; FEMALE; HIV INFECTIONS; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

CAMBODIA; PHNOM PENH;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84874636440     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.12.111153     Document Type: Article

References (50)

1. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 2010;375:1906-19. doi:10.1016/S0140-6736(10)60409-6 PMID:20488516
2. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A etal. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706. doi:10.1056/NEJMoa0905848 PMID:20181971
3. Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV. HIV and tuberculosis-science and implementation to turn the tide and reduce deaths. J Int AIDS Soc 2012;15:17396. PMID:22905358
4. Global tuberculosis control. WHO report. Geneva: World Health Organization; 2011.
5. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM etal. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011;15:571-81. doi:10.5588/ijtld.10.0483 PMID:21756508
6. Murphy RA, Sunpath H, Taha B, Kappagoda S, Maphasa KT, Kuritzkes DR et al. Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010;14:903-8. PMID:20550776
7. Chakaya JM, Mansoer JR, Scano F, Wambua N, L'Herminez R, Odhiambo J etal. National scale-up of HIV testing and provision of HIV care to tuberculosis patients in Kenya. Int J Tuberc Lung Dis 2008;12:424-9. PMID:18371269
8. Njozing NB, Miguel SS, Tih PM, Hurtig AK. Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon. BMC Public Health 2010;10:129. doi:10.1186/1471-2458-10-129 PMID:20226022
9. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 Revision. Geneva: World Health Organization; 2010.
10. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL etal. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501. doi:10.1056/NEJMoa1014181 PMID:22010915
11. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E etal.; CAMELIA Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81. doi:10.1056/NEJMoa1013911 PMID:22010913
12. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS etal.; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91. doi:10.1056/NEJMoa1013607 PMID:22010914
13. Török ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med 2011;365:1538-40. doi:10.1056/NEJMe1109546 PMID:22010921
14. Lawn SD, Campbell L, Kaplan R, Little F, Morrow C, Wood R; IeDEA-Southern Africa. Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township. BMC Infect Dis 2011;11:258. doi:10.1186/1471-2334-11-258 PMID:21957868
15. Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012;26:2121-33. doi:10.1097/QAD.0b013e3283565dd1 PMID:22695302
16. Loveday M, Zweigenthal VTB. TB and HIV integration: obstacles and possible solutions to implementation in South Africa. Trop Med Int Health 2011;16:431-8. doi:10.1111/j.1365-3156.2010.02721.x PMID:21255204
17. Howard AA, El-Sadr WM. Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis 2010;50:S238-44. doi:10.1086/651497 PMID:20397954
18. Uyei J, Coetzee D, Macinko J, Guttmacher S. Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2011;11:855-67. doi:10.1016/S1473-3099(11)70145-1 PMID:22035614
19. Chilton D, Edwards SG, Pellegrino P, Miller RF. Factors influencing delay in initiating antiretroviral therapy among HIV infected patients coinfected with tuberculosis. Thorax 2008;63:935-6. doi:10.1136/thx.2008.104232 PMID:18820121
20. Tayler-Smith K, Zachariah R, Manzi M, Kizito W, Vandenbulcke A, Sitienei J etal. Antiretroviral treatment uptake and attrition among HIV-positive patients with tuberculosis in Kibera, Kenya. Trop Med Int Health 2011;16:1380-3. doi:10.1111/j.1365-3156.2011.02863.x PMID:21831116
21. Thai S, Koole O, Un P, Ros S, De Munter P, Van Damme W etal. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009;14:1048-58. doi:10.1111/j.1365-3156.2009.02334.x PMID:19573140
22. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, Giddy J etal. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009;51:135-9. doi:10.1097/QAI.0b013e3181a44ef2 PMID:19504725
23. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011;8:e1001056. doi:10.1371/journal.pmed.1001056 PMID:21811403
24. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005;19:2141-8. doi:10.1097/01.aids.0000194802.89540.e1 PMID:16284464
25. Zachariah R, Tayler-Smith K, Manzi M, Massaquoi M, Mwagomba B, van Griensven J etal. Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Trans R Soc Trop Med Hyg 2011;105:421-30. doi:10.1016/j.trstmh.2011.04.014 PMID:21724219
26. Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, Meintjes G. Assessment at antiretroviral clinics during TB treatment reduces loss to follow-up among HIV-infected patients. PLoS One 2012;7:e37634. doi:10.1371/journal.pone.0037634 PMID:22719843
27. Tsurugi Y, Eam KK, Eang MT, Uehara R, Nakamura Y, Murakami K etal. Evaluation of collaborative tuberculosis and human immunodeficiency virus activities in Phnom Penh, Cambodia. Int J Tuberc Lung Dis 2011;15:1535-9. doi:10.5588/ijtld.10.0455 PMID:22008769
28. Phiri S, Khan PY, Grant AD, Gareta D, Tweya H, Kalulu M etal. Integrated tuberculosis and HIV care in a resource-limited setting: experience from the Martin Preuss centre, Malawi. Trop Med Int Health 2011;16:1397-403. doi:10.1111/j.1365-3156.2011.02848.x PMID:21806742
29. Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman AI etal. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr 2012;60:e29-35. PMID:22395671
30. Gandhi NR, Moll AP, Lalloo U, Pawinski R, Zeller K, Moodley P etal.; Tugela Ferry Care and Research (TFCaRes) Collaboration. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009;50:37-43. doi:10.1097/QAI.0b013e31818ce6c4 PMID:19295333
31. Lawn SD, Campbell L, Kaplan R, Boulle A, Cornell M, Kerschberger B etal.; International Epidemiological Databases to Evaluate AIDS-Southern Africa. Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa. J Acquir Immune Defic Syndr 2011;57:136-40. doi:10.1097/QAI.0b013e3182199ee9 PMID:21436714
32. Kerschberger B, Hilderbrand K, Boulle AM, Coetzee D, Goemaere E, De Azevedo V etal. The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study. PLoS One 2012;7:e46988. doi:10.1371/journal.pone.0046988 PMID:23071690
33. Huerga H, Spillane H, Guerrero W, Odongo A, Varaine F. Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya. Int J Tuberc Lung Dis 2010;14:611-5. PMID:20392355
34. Louwagie G, Girdler-Brown B, Odendaal R, Rossouw T, Johnson S, Van der Walt M. Missed opportunities for accessing HIV care among Tshwane tuberculosis patients under different models of care. Int J Tuberc Lung Dis 2012;16:1052-8. doi:10.5588/ijtld.11.0753 PMID:22691870
35. Sunpath H, Edwin C, Chelin N, Nadesan S, Maharaj R, Moosa Y etal. Operationalizing early antiretroviral therapy in HIV-infected in-patients with opportunistic infections including tuberculosis. Int J Tuberc Lung Dis 2012;16:917-23. doi:10.5588/ijtld.11.0651 PMID:22687498
36. Pevzner ES, Vandebriel G, Lowrance DW, Gasana M, Finlay A. Evaluation of the rapid scale-up of collaborative TB/HIV activities in TB facilities in Rwanda, 2005-2009. BMC Public Health 2011;11:550. doi:10.1186/1471-2458-11-550 PMID:21745385
37. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization; 2006.
38. Treatment of tuberculosis: guidelines for national programmes. Fourth Edition. Geneva: World Health Organization; 2010.
39. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2006 revision. Geneva: World Health Organization; 2006.
40. Koole O, Thai S, Khun KE, Pe R, van Griensven J, Apers L etal. Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults. PLoS One 2011;6:e18502. doi:10.1371/journal.pone.0018502 PMID:21494694
41. Lynen L, An S, Koole O, Thai S, Ros S, De Munter P etal. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009;52:40-8. doi:10.1097/QAI.0b013e3181af6705 PMID:19550349
42. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One 2012;7:e30647. doi:10.1371/journal.pone.0030647 PMID:22303447
43. van Griensven J, Thai S. Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg 2011;105:694-703. doi:10.1016/j.trstmh.2011.08.007 PMID:21962614
44. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170:244-56. doi:10.1093/aje/kwp107 PMID:19494242
45. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997;16:901-10. doi:10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M PMID:9160487
46. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP etal. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011;8:e1000391. doi:10.1371/journal.pmed.1000391 PMID:21267059
47. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012.
48. Degu WA, Lindquist L, Aderaye G, Aklillu E, Wold AH, Ali GY et al. Ramdomized clinical trial to determine efficacy and safety of ART 1 week after TB therapy in patients with CD4 counts < 200 cells/μL. In: Fourteenth Conference on Retroviruses and Opportunistic Infections [Internet]; 3-7 March 2012; Seattle, United States of America. Available from: http://retroconference.org/2007/index.asp?page=310 [accessed 18 December 2012].
49. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P etal.; TIME Study Team. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012;60:377-83. PMID:22592586
50. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS 2012;26:2059-67. doi:10.1097/QAD.0b013e3283578b9b PMID:22781227